Related Experiment Video
Updated: Aug 5, 2026
08:55
The Colon-26 Carcinoma Tumor-bearing Mouse as a Model for the Study of Cancer Cachexia
Published on: November 30, 2016
GDF15: A Hijacked Metabo-Hormone Orchestrating Cachexia and Immunosuppression in Cancer
Dong-Yang Qi1,2, Yong-Fei Wang1,2, Wei-Lin Jin1,2
1The First Clinical Medical College, Lanzhou University, Lanzhou 730000, China.
Biomolecules
|July 28, 2026
Summary
Growth differentiation factor 15 (GDF15) hijacks cancer stress signals, causing cachexia and immune suppression. Targeting the GDF15-GFRAL axis may simultaneously treat both conditions and improve cancer therapy.
Area of Science:
- Oncology
- Metabolism
- Immunology
Background:
- Cancer causes systemic burdens like cachexia and immunosuppression, worsening patient outcomes.
- These debilitating syndromes are interconnected and often studied in isolation.
- Growth differentiation factor 15 (GDF15) shows dual actions in immunity and metabolism.
Purpose of the Study:
- Propose GDF15 as a central metaboceptive hub hijacked by tumors.
- Investigate GDF15's role in integrating oncogenic stress signals.
- Explore the GDF15-GFRAL axis as a therapeutic target.
Main Methods:
- Analysis of GDF15's systemic effects on brain-body communication via GFRAL.
- Assessment of GDF15's impact on T cell cytotoxicity and regulatory T cells in the tumor microenvironment.
- Evaluation of the interconnectedness of GDF15-mediated cachexia and immunosuppression.
Main Results:
- GDF15 disrupts brainstem GFRAL signaling, driving anorexia and tissue wasting (cachexia).
- GDF15 suppresses anti-tumor immunity by impairing T cells and increasing regulatory T cells.
- Cachexia and immunosuppression driven by GDF15 form a self-reinforcing detrimental cycle.
Conclusions:
- The GDF15-GFRAL axis is a central mediator of cancer-induced cachexia and immunosuppression.
- Targeting the GDF15-GFRAL axis offers a dual therapeutic strategy to combat cancer-related wasting and immune evasion.
- This approach may improve patient quality of life and enhance the efficacy of cancer therapies.
Keywords:
GDF15GFRALbrain–body communicationcancer cachexiaimmunotherapymetaboceptionmuscle wastingneuroendocrinologytumor microenvironmentMore Related Videos
09:29Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
08:17A Human Peripheral Blood Mononuclear Cell (PBMC) Engrafted Humanized Xenograft Model for Translational Immuno-oncology (I-O) Research
Published on: August 15, 2019
Related Concept Videos
02:38Mitogens and the Cell Cycle
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:53Adaptive Mechanisms in Cancer Cells
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...